Literature DB >> 3030944

In vitro antigenic modulation of human neuroblastoma cells induced by IFN-gamma, retinoic acid and dibutyryl cyclic AMP.

N Gross, D Beck, S Favre, S Carrel.   

Abstract

Testing with a panel of 26 monoclonal antibodies (MAbs) showed the antigenic profile of 13 human neuroblastoma cell lines to be characterized by a generally poor antigenic expression; therefore, Interferon-gamma (IFN-gamma), dibutyryl cyclic-AMP and retinoic acid were used to analyse the modulation of surface antigenic expression during differentiation. Treatment of neuroblastoma cell lines with IFN-gamma resulted mainly in induction or increase of class-I MHC antigenic expression. Induction of class-II MHC antigens was obtained on only one neuroblastoma cell line out of 13, thus representing an exceptional event. An increase in some other antigens expressed by neuroblastoma cell lines was also observed. In contrast, and in addition to morphological maturation, treatment of these cell lines with the differentiation inducer dibutyryl-cyclic-AMP (dbc-AMP), resulted in general down-modulation of antigenic expression, particularly of neuroblastoma-associated 5A7 or Leu7 antigens. Retinoic acid treatment had no significant effect on MHC antigens, but it decreased expression of 5A7 and Leu7 antigens, and markedly increased the expression of the melanoma-associated antigen Me14-D12. The similarity between the antigenic profile of in vitro differentiated neuroblastoma cells and that of mature ganglioneuroma cells suggests that compounds like cyclic-AMP or retinoic acid are excellent tools for further investigations of the mechanisms of neuroblastoma differentiation and might have important clinical applications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030944     DOI: 10.1002/ijc.2910390420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Scanning electron microscopic evidence for neural differentiation in Ewing's sarcoma cell lines.

Authors:  S Navarro; M González-Devesa; A Ferrández-Izquierdo; T J Triche; A Llombart-Bosch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples.

Authors:  D Beck; O Maritaz; N Gross; M Favrot; N Vultier; C Bailly; I Villa; O Gentilhomme; T Philip
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

3.  Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.

Authors:  V Feyles; W T Dixon; L K Sikora; R C McGarry; L M Jerry
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells.

Authors:  N I Obiri; J P Siegel; F Varricchio; R K Puri
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

5.  Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.

Authors:  D S Hoon; Y Hayashi; T Morisaki; L J Foshag; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

6.  Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.

Authors:  Julie Liberman; Hervé Sartelet; Marjorie Flahaut; Annick Mühlethaler-Mottet; Aurélie Coulon; Carine Nyalendo; Gilles Vassal; Jean-Marc Joseph; Nicole Gross
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

7.  Increased expression of trk proto-oncogene by gamma-interferon in human neuroblastoma cell lines.

Authors:  A Shikata; T Sugimoto; H Hosoi; Y Sotozono; T Shikata; T Sawada; L F Parada
Journal:  Jpn J Cancer Res       Date:  1994-02

Review 8.  β adrenergic receptor modulated signaling in glioma models: promoting β adrenergic receptor-β arrestin scaffold-mediated activation of extracellular-regulated kinase 1/2 may prove to be a panacea in the treatment of intracranial and spinal malignancy and extra-neuraxial carcinoma.

Authors:  George Zaki Ghali; Michael George Zaki Ghali
Journal:  Mol Biol Rep       Date:  2020-04-18       Impact factor: 2.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.